Colorectal Cancer
Advertisement
Dr. Arun Nagarajan explains how disparities in testing can affect survival and treatment outcomes for patients with mCRC.
The timing of stoma closure does not appear to affect long-term bowel function and quality of life.
The potential uses of bexarotene, a retinoid, for patients with colon cancer have not been adequately explored.
iTNT regimens were found to improve CR rates in patients with pMMR/MSS LARC compared with historical benchmark data.
The effects of targeted therapies are deterred by a rapid emergence of resistance.
The US FDA recently granted approval for the combination of adagrasib and cetuximab for mCRC with KRAS G12C mutation.
In patients with mismatch repair-deficient colorectal cancer, PD-1 blockade has demonstrated positive benefits.
The panel concludes with the challenges of implementing cutting-edge research into colorectal cancer care and practice.
The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.
The panel expands on the incorporation of ctDNA in the CRC adjuvant setting, highlighting its prognostic value.
The panel details strategies for managing oligometastatic CRC, emphasizing the importance of a multidisciplinary approach.
The panel swaps opinions on advancements in EGFR and KRAS inhibitors, as well as the importance of NGS and liquid biopsy.
The panel focuses on the evolution of CRC treatment paradigms, including advances in chemo, biologic agents, and more.
Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
Dr. Barnell gives an update on the FDA approval of ColoSense and how the test can aid in public health initiatives.
Dr. Eng comments on how she approaches treatment considerations and management for her younger patients with colon cancer.
Dr. Eng explains how she makes sense of the stage 4 third-line therapy options to administer to her colon cancer patients.
Dr. Eng shares what the COMMIT study suggest about colon cancer and this study's applicability outside of liver metastasis.
Dr. Eng provides her thoughts on ctDNA upfront, sequential, and combined with NGS testing for patients with colon cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.